Payment overview · 2025
General Payments
$72.52
4 reported records · 1 companies
Healthcare provider profile · identity verified
Alexander Vaysman, M.D
Allopathic & Osteopathic Physicians|Internal Medicine · FAR ROCKAWAY, NY · NPI 1396793113
Verified facts
What the public records show
CMS Open Payments records show Alexander Vaysman, M.D received $72.52 in general payments during 2025 across 4 reported records.
Lilly USA, LLC accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $72.52 | 100.0% | 4 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $72.52 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $72.52 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $56.53 | 3 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
71 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 1264 | 325 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1201 | 335 |
| Losartan Potassium | Losartan Potassium | 865 | 217 |
| Metformin Hcl | Metformin Hcl | 673 | 192 |
| Omeprazole | Omeprazole | 645 | 162 |
| Hydrochlorothiazide | Hydrochlorothiazide | 534 | 150 |
| Metoprolol Succinate | Metoprolol Succinate | 481 | 124 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 445 | 104 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 397 | 110 |
| Januvia | Sitagliptin Phosphate | 379 | 86 |
| Lisinopril | Lisinopril | 378 | 90 |
| Ozempic | Semaglutide | 322 | 68 |
| Gabapentin | Gabapentin | 287 | 79 |
| Levothyroxine Sodium | Levothyroxine Sodium | 274 | 65 |
| Tamsulosin Hcl | Tamsulosin Hcl | 267 | 64 |
| Azithromycin | Azithromycin | 254 | 172 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 253 | 59 |
| Fluticasone Propionate | Fluticasone Propionate | 245 | 86 |
| Simvastatin | Simvastatin | 241 | 63 |
| Methylprednisolone | Methylprednisolone | 234 | 161 |
| Meloxicam | Meloxicam | 218 | 83 |
| Baclofen | Baclofen | 215 | 87 |
| Montelukast Sodium | Montelukast Sodium | 209 | 51 |
| Halobetasol Propionate | Halobetasol Propionate | 175 | 66 |
| Ibuprofen | Ibuprofen | 172 | 81 |
| Clopidogrel | Clopidogrel Bisulfate | 159 | 44 |
| Glipizide | Glipizide | 157 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 153 | 42 |
| Meclizine Hcl | Meclizine Hcl | 146 | 47 |
| Enalapril Maleate | Enalapril Maleate | 130 | 36 |
| Celecoxib | Celecoxib | 129 | 66 |
| Ammonium Lactate | Ammonium Lactate | 125 | 31 |
| Diclofenac Sodium | Diclofenac Sodium | 119 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 111 | 36 |
| Furosemide | Furosemide | 104 | 30 |
| Trazodone Hcl | Trazodone Hcl | 102 | 40 |
| Donepezil Hcl | Donepezil Hcl | 100 | 31 |
| Carvedilol | Carvedilol | 96 | 29 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 93 | 24 |
| Valsartan | Valsartan | 93 | 24 |
| Buspirone Hcl | Buspirone Hcl | 91 | 27 |
| Clonidine Hcl | Clonidine Hcl | 90 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 84 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 83 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 83 | 22 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 81 | 39 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 80 | 22 |
| Famotidine | Famotidine | 80 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 78 | 23 |
| Eliquis | Apixaban | 78 | 17 |
| Nifedipine Er | Nifedipine | 75 | 20 |
| Cilostazol | Cilostazol | 74 | 18 |
| Jardiance | Empagliflozin | 71 | 17 |
| Naproxen | Naproxen | 69 | 30 |
| Allopurinol | Allopurinol | 66 | 19 |
| Clotrimazole | Clotrimazole | 64 | 23 |
| Alendronate Sodium | Alendronate Sodium | 62 | 14 |
| Ezetimibe | Ezetimibe | 62 | 13 |
| Ketoconazole | Ketoconazole | 62 | 28 |
| Linzess | Linaclotide | 61 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 60 | 11 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 59 | 23 |
| Breo Ellipta | Fluticasone/Vilanterol | 54 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 54 | 11 |
| Memantine Hcl | Memantine Hcl | 54 | 11 |
| Levofloxacin | Levofloxacin | 53 | 50 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 52 | 13 |
| Finasteride | Finasteride | 51 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 51 | suppressed |
| Levetiracetam | Levetiracetam | 50 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 49 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 48 | suppressed |
| Atenolol | Atenolol | 47 | 15 |
| Glipizide Er | Glipizide | 47 | 11 |
| Metformin Hcl Er | Metformin Hcl | 47 | 13 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 46 | 18 |
| Chlorthalidone | Chlorthalidone | 46 | 12 |
| Dexlansoprazole Dr | Dexlansoprazole | 46 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 43 | 11 |
| Metformin Er Gastric | Metformin Hcl | 43 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 43 | 38 |
| Tradjenta | Linagliptin | 43 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 42 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 42 | suppressed |
| Nabumetone | Nabumetone | 42 | 20 |
| Sertraline Hcl | Sertraline Hcl | 42 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 41 | suppressed |
| Amoxicillin | Amoxicillin | 40 | 38 |
| Single Use Swab | Alcohol Antiseptic Pads | 40 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 39 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 39 | suppressed |
| Prednisone | Prednisone | 39 | 24 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 37 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 37 | 12 |
| Glimepiride | Glimepiride | 36 | 11 |
| Creon | Lipase/Protease/Amylase | 35 | suppressed |
| Ramipril | Ramipril | 34 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 34 | 11 |
| Diclofenac Sodium Er | Diclofenac Sodium | 33 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 32 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Myrbetriq | Mirabegron | 31 | suppressed |
| Nitroglycerin | Nitroglycerin | 31 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 31 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 30 | suppressed |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 25 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 29 | 12 |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 29 | 23 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 14 |
| Metronidazole | Metronidazole | 28 | 16 |
| Mirtazapine | Mirtazapine | 28 | 12 |
| Novolog Flexpen | Insulin Aspart | 28 | 13 |
| Entresto | Sacubitril/Valsartan | 27 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 27 | 21 |
| Risperidone | Risperidone | 27 | 13 |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 26 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 26 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 25 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Telmisartan | Telmisartan | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 18 |
| Memantine Hcl Er | Memantine Hcl | 23 | suppressed |
| Restasis | Cyclosporine | 23 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 22 | suppressed |
| Cefadroxil | Cefadroxil | 21 | 17 |
| Folic Acid | Folic Acid | 21 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 21 | suppressed |
| Latanoprost | Latanoprost | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Glyburide | Glyburide | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Methotrexate | Methotrexate Sodium | 19 | suppressed |
| Metolazone | Metolazone | 19 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Dutasteride | Dutasteride | 18 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Ranolazine Er | Ranolazine | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Methimazole | Methimazole | 17 | suppressed |
| Repaglinide | Repaglinide | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Acarbose | Acarbose | 16 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 16 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 15 | suppressed |
| Potassium Chloride | Potassium Chloride | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | 11 |
| Tobramycin | Tobramycin | 14 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 11 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 13 | suppressed |
| Pulmicort Flexhaler | Budesonide | 13 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $72.52 · 4 records | Lilly USA, LLC | MOUNJARO, ZEPBOUND | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error